With this appeal in mind, Yang and colleagues [89] reported that a supramolecular “trident” (IND-GDFDFDY-DPPA-1), consisting of DPPA-1 (as the antagonist against PD-L1), indoximod (as the indoleamine 2,3-dioxygenase inhibitor), and D-tetrapeptide of GDFDFDY (as self-assembly module), displays triple functions for boosting the tumor immunotherapy. This evidence concerns the gene CD274 and neoplasm.